AR072993A1 - Composicion farmaceutica inyectable de taxanos. composicion para perfusion. - Google Patents
Composicion farmaceutica inyectable de taxanos. composicion para perfusion.Info
- Publication number
- AR072993A1 AR072993A1 ARP090103052A ARP090103052A AR072993A1 AR 072993 A1 AR072993 A1 AR 072993A1 AR P090103052 A ARP090103052 A AR P090103052A AR P090103052 A ARP090103052 A AR P090103052A AR 072993 A1 AR072993 A1 AR 072993A1
- Authority
- AR
- Argentina
- Prior art keywords
- carcinoma
- citrate
- pharmaceutical composition
- composition according
- group
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 6
- 230000010412 perfusion Effects 0.000 title 1
- -1 sorbitan fatty acid Chemical class 0.000 abstract 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 6
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 4
- 229930195729 fatty acid Natural products 0.000 abstract 4
- 239000000194 fatty acid Substances 0.000 abstract 4
- 239000002202 Polyethylene glycol Substances 0.000 abstract 3
- 229920001223 polyethylene glycol Polymers 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 229940123237 Taxane Drugs 0.000 abstract 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 abstract 2
- 125000005907 alkyl ester group Chemical group 0.000 abstract 2
- 238000001802 infusion Methods 0.000 abstract 2
- 239000004094 surface-active agent Substances 0.000 abstract 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 2
- HDDLVZWGOPWKFW-UHFFFAOYSA-N trimethyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound COC(=O)CC(O)(C(=O)OC)CC(=O)OC HDDLVZWGOPWKFW-UHFFFAOYSA-N 0.000 abstract 2
- BKVAAWMQOQLENB-UHFFFAOYSA-N 15-hydroxy stearic acid Chemical compound CCCC(O)CCCCCCCCCCCCCC(O)=O BKVAAWMQOQLENB-UHFFFAOYSA-N 0.000 abstract 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 206010073069 Hepatic cancer Diseases 0.000 abstract 1
- 208000007766 Kaposi sarcoma Diseases 0.000 abstract 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 229920003171 Poly (ethylene oxide) Chemical class 0.000 abstract 1
- 229920001214 Polysorbate 60 Polymers 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000008135 aqueous vehicle Substances 0.000 abstract 1
- 201000001531 bladder carcinoma Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 201000008275 breast carcinoma Diseases 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 229950010692 docetaxel trihydrate Drugs 0.000 abstract 1
- XCDIRYDKECHIPE-QHEQPUDQSA-N docetaxel trihydrate Chemical compound O.O.O.O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 XCDIRYDKECHIPE-QHEQPUDQSA-N 0.000 abstract 1
- 150000002170 ethers Chemical class 0.000 abstract 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 208000010749 gastric carcinoma Diseases 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 201000002250 liver carcinoma Diseases 0.000 abstract 1
- 201000005296 lung carcinoma Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 239000004530 micro-emulsion Substances 0.000 abstract 1
- 208000020717 oral cavity carcinoma Diseases 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 229920001983 poloxamer Polymers 0.000 abstract 1
- 239000008389 polyethoxylated castor oil Substances 0.000 abstract 1
- 229920000223 polyglycerol Polymers 0.000 abstract 1
- 201000001514 prostate carcinoma Diseases 0.000 abstract 1
- 201000010174 renal carcinoma Diseases 0.000 abstract 1
- 201000000498 stomach carcinoma Diseases 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 abstract 1
- 239000001069 triethyl citrate Substances 0.000 abstract 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 abstract 1
- 235000013769 triethyl citrate Nutrition 0.000 abstract 1
- TUUQISRYLMFKOG-UHFFFAOYSA-N trihexyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCCCCCOC(=O)CC(C(=O)OCCCCCC)(OC(C)=O)CC(=O)OCCCCCC TUUQISRYLMFKOG-UHFFFAOYSA-N 0.000 abstract 1
- AMMPRZCMKXDUNE-UHFFFAOYSA-N trihexyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CCCCCCOC(=O)CC(O)(C(=O)OCCCCCC)CC(=O)OCCCCCC AMMPRZCMKXDUNE-UHFFFAOYSA-N 0.000 abstract 1
- APVVRLGIFCYZHJ-UHFFFAOYSA-N trioctyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CCCCCCCCOC(=O)CC(O)(C(=O)OCCCCCCCC)CC(=O)OCCCCCCCC APVVRLGIFCYZHJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicacion 1: Composicion farmacéutica estable de administracion parenteral, que comprende un taxano, al menos un tensioactivo, al menos un éster alquílico del ácido cítrico y etanol. Reivindicacion 4: Composicion farmacéutica segun cualquiera de las reivindicaciones anteriores, donde el taxano se selecciona del grupo formado por paclitaxel, docetaxel anhidro o docetaxel trihidrato. Reivindicacion 10: Composicion farmacéutica segun cualquiera de las reivindicaciones anteriores, donde el tensioactivo se selecciona del grupo formado por monoésteres de ácidos grasos de polioxietilen sorbitano, monoésteres de ácidos grasos de sorbitano, polietilenglicol 15-hidroxiestearato, polietilenglicol ésteres de ácidos grasos, ésteres de polioxietilen glicoles, aceites de ricino polietoxilados, poliglicerol ésteres de ácidos grasos, polietilenglicol éteres, poloxámeros, polioxietilen feniléteres o sus mezclas. Reivindicacion 14: Composicion farmacéutica segun cualquiera de las reivindicaciones anteriores, donde el éster alquílico del ácido cítrico se selecciona del grupo formado por trietil citrato, acetil trietil citrato, tributil citrato, acetil tributil citrato, trimetil citrato, trihexil citrato, acetil trihexil citrato, trioctil citrato, acetil trioctil citrato o mezclas de ellos. Reivindicacion 19: Composicion farmacéutica segun cualquiera de las reivindicaciones anteriores, que comprende al menos un ácido que ajusta el pH de la composicion a un valor comprendido entre 2 y 6. Reivindicacion 25: Composicion farmacéutica segun la reivindicacion 28, donde el tumor canceroso se selecciona del grupo formado por carcinoma de mama, carcinoma de ovario, carcinoma de vejiga, carcinoma de rinon, carcinoma de prostata, carcinoma de estomago, carcinoma de colon, carcinoma de páncreas, carcinoma de hígado, carcinoma de pulmon, sarcoma de Kaposi, melanoma, carcinoma de cuello, garganta y boca, carcinoma cerebral, glioblastoma y linfoma. Reivindicacion 26: Composicion para perfusion caracterizada porque es una microemulsion o microsuspension obtenida por mezcla directa de la composicion segun cualquiera de las reivindicaciones anteriores y un vehículo acuoso adecuado para la perfusion intravenosa.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200802389A ES2344674B1 (es) | 2008-08-07 | 2008-08-07 | Composicion farmaceutica inyectable de taxanos. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072993A1 true AR072993A1 (es) | 2010-10-06 |
Family
ID=41110757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103052A AR072993A1 (es) | 2008-08-07 | 2009-08-07 | Composicion farmaceutica inyectable de taxanos. composicion para perfusion. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110130446A1 (es) |
| EP (1) | EP2306976A2 (es) |
| JP (1) | JP2011529930A (es) |
| AR (1) | AR072993A1 (es) |
| AU (1) | AU2009278202A1 (es) |
| BR (1) | BRPI0911930A2 (es) |
| CA (1) | CA2732901A1 (es) |
| ES (1) | ES2344674B1 (es) |
| IL (1) | IL211050A0 (es) |
| MX (1) | MX2011001402A (es) |
| WO (1) | WO2010015400A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2798180A1 (en) | 2010-05-03 | 2011-11-10 | Teikoku Pharma Usa, Inc. | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
| WO2012156999A1 (en) * | 2011-05-19 | 2012-11-22 | Manu Chaudhary | Ready to use docetaxel formulation |
| JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
| US10188626B2 (en) | 2015-11-03 | 2019-01-29 | Cipla Limited | Stabilized cabazitaxel formulations |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2678833B1 (fr) | 1991-07-08 | 1995-04-07 | Rhone Poulenc Rorer Sa | Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes. |
| EP0674510B1 (en) * | 1992-11-27 | 1998-08-05 | Napro Biotherapeutics, Inc. | Injectable composition comprising paclitaxel |
| FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
| FR2718963B1 (fr) * | 1994-04-25 | 1996-05-24 | Rhone Poulenc Rorer Sa | Nouvelle composition pharmaceutique à base de taxoïdes. |
| HU215966B (hu) * | 1994-11-21 | 1999-07-28 | BIOGAL Gyógyszergyár Rt. | Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum |
| US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| CN1209059A (zh) | 1995-12-21 | 1999-02-24 | 基因实验室技术有限公司 | 紫杉烷类组合物及方法 |
| US5922754A (en) * | 1998-10-02 | 1999-07-13 | Abbott Laboratories | Pharmaceutical compositions containing paclitaxel |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| DE19925211B4 (de) | 1999-06-01 | 2006-01-12 | PBS Pharmaceutical Bulk Substances SA | Kit zur Herstellung einer Formulierung von Paclitaxel |
| EP1479382A1 (en) * | 1999-06-18 | 2004-11-24 | IVAX Research, Inc. | Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same |
| WO2001072300A1 (en) | 2000-03-24 | 2001-10-04 | Baker Norton Pharmaceuticals, Inc. | Uses of metal salts to stabilize taxane-based compositions |
| KR100774366B1 (ko) * | 2001-09-10 | 2007-11-08 | 주식회사 중외제약 | 파클리탁셀 주사제 조성물 |
| BR0215184A (pt) | 2001-12-20 | 2006-06-06 | Bristol Myers Squibb Co | composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada |
| CA2471572A1 (en) | 2001-12-28 | 2003-07-17 | Ivax Research, Inc. | Taxane based compositions and methods of use |
| US6960346B2 (en) * | 2002-05-09 | 2005-11-01 | University Of Tennessee Research Foundation | Vehicles for delivery of biologically active substances |
| US20040127551A1 (en) * | 2002-12-27 | 2004-07-01 | Kai Zhang | Taxane-based compositions and methods of use |
| EP1622540A4 (en) * | 2003-03-11 | 2009-12-30 | Qlt Usa Inc | FORMULATIONS FOR CELL-PLAN-DEPENDENT CANCER |
| US20060292186A1 (en) * | 2003-08-29 | 2006-12-28 | Novagali Pharma Sa | Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
| EP1510206A1 (en) | 2003-08-29 | 2005-03-02 | Novagali Pharma SA | Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
| US20050281879A1 (en) * | 2003-11-14 | 2005-12-22 | Guohua Chen | Excipients in drug delivery vehicles |
| KR20050099311A (ko) | 2004-04-09 | 2005-10-13 | 에이엔에이치 케어연구소(주) | 주사제용 항암제 조성물 |
| GB0517092D0 (en) * | 2005-08-19 | 2005-09-28 | Novartis Ag | New compositions containing taxane derivatives |
| CN1857222B (zh) * | 2006-06-05 | 2010-05-12 | 中国医药研究开发中心有限公司 | 多西紫杉醇静脉注射亚微乳剂及其制备方法 |
-
2008
- 2008-08-07 ES ES200802389A patent/ES2344674B1/es active Active
-
2009
- 2009-08-06 BR BRPI0911930A patent/BRPI0911930A2/pt not_active IP Right Cessation
- 2009-08-06 US US13/057,661 patent/US20110130446A1/en not_active Abandoned
- 2009-08-06 MX MX2011001402A patent/MX2011001402A/es not_active Application Discontinuation
- 2009-08-06 EP EP09777693A patent/EP2306976A2/en not_active Withdrawn
- 2009-08-06 AU AU2009278202A patent/AU2009278202A1/en not_active Abandoned
- 2009-08-06 WO PCT/EP2009/005691 patent/WO2010015400A2/en active Application Filing
- 2009-08-06 JP JP2011521479A patent/JP2011529930A/ja active Pending
- 2009-08-06 CA CA2732901A patent/CA2732901A1/en not_active Abandoned
- 2009-08-07 AR ARP090103052A patent/AR072993A1/es unknown
-
2011
- 2011-02-03 IL IL211050A patent/IL211050A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2344674B1 (es) | 2011-06-29 |
| AU2009278202A1 (en) | 2010-02-11 |
| US20110130446A1 (en) | 2011-06-02 |
| EP2306976A2 (en) | 2011-04-13 |
| BRPI0911930A2 (pt) | 2015-10-06 |
| MX2011001402A (es) | 2011-05-30 |
| JP2011529930A (ja) | 2011-12-15 |
| ES2344674A1 (es) | 2010-09-02 |
| CA2732901A1 (en) | 2010-02-11 |
| WO2010015400A3 (en) | 2010-08-12 |
| IL211050A0 (en) | 2011-04-28 |
| WO2010015400A2 (en) | 2010-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072993A1 (es) | Composicion farmaceutica inyectable de taxanos. composicion para perfusion. | |
| ES2580481T3 (es) | Derivados de aminoquinazolina y sus sales, y métodos de uso | |
| UY29125A1 (es) | Procedimiento de preparacion de un producto en polvo | |
| AR075613A1 (es) | Composicion y suministro de drogas de bifosfonato. metodo de tratamiento | |
| NZ602382A (en) | Methods of treatment of hepatocellular carcinoma | |
| PE20170312A1 (es) | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso | |
| RU2019114963A (ru) | Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo | |
| JP2015033646A5 (es) | ||
| BR112018008714A2 (pt) | inibidores de isoindolina, azaisoindolina, dihidroindenona e dihidroazaindenona da mnk1 e mnk2 | |
| CO2019004190A2 (es) | Formulaciones liposomales para uso en el tratamiento del cáncer | |
| RS20080167A (en) | Novel improved compositions for cancer therapy | |
| BR112013026363A2 (pt) | nanossuspensões de fármaco criodessecadas | |
| RU2019133284A (ru) | Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства | |
| WO2015051543A8 (en) | Cancer treatment with combination of plinabulin and taxane | |
| SA515370134B1 (ar) | تركيبة صيدلانية تحتوي على عامل علاجي قائم على الهيموغلوبين المعدل لعلاج السرطان المستهدف والتصوير التشخيصي | |
| NZ701205A (en) | Optimised subcutaneous therapeutic agents | |
| PE20120895A1 (es) | Uso de n-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina en el tratamiento de cancer resistente al agente antimitotico | |
| AR078824A1 (es) | Compuesto de cabazitaxel y sus usos | |
| JP2005511597A5 (es) | ||
| MX2018003452A (es) | Composiciones de taxano orales y metodos. | |
| Zhong et al. | αvβ3 integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo | |
| NZ772450A (en) | High surface-area lyophilized compositions comprising arsenic for oral administration in patients | |
| EP1703904B1 (en) | Taxoid-fatty acid conjugates and pharmaceutical compositions thereof | |
| WO2013113030A3 (en) | Fads regulation | |
| RU2010140611A (ru) | Комбинированное применение производных холестанола |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |